A Novel Immune-Based Therapy for Stroke Induces Neuroprotection and Supports Neurogenesis

Yaniv Ziv, MSc; Arseny Finkelstein, BSc; Yona Geffen, PhD; Jonathan Kipnis, PhD; Igor Smirnov, MDV; Suzi Shpilman, MSc; Irena Vertkin, MSc; Michal Kimron, MSc; Aya Lange, MSc; Torsten Hecht, PhD; Klaus G. Reyman, PhD; Jonathan B. Marder, PhD; Michal Schwartz, PhD; Eti Yoles, PhD

Abstract—The ability of the central nervous system to cope with stressful conditions was shown to be dependent on proper T-cell–mediated immune response. Because the therapeutic window for neuroprotection after acute insults such as stroke is relatively narrow, we searched for a procedure that would allow the relevant T cells to be recruited rapidly. Permanent middle cerebral artery occlusion was induced in adult rats. To facilitate a rapid poststroke T cell activity, rats were treated with poly-YE using different regimens. Control and poly-YE–treated rats were assessed for functional recovery using neurological severity score and Morris water maze. Neuroprotection, neurogenesis, growth factor expression, and microglial phenotype were assessed using histological and immunofluorescence methods. Administration of poly-YE as late as 24 hours after middle cerebral artery occlusion yielded a beneficial effect manifested by better neurological performance, reduced neuronal loss, attenuation of behavioral deficits, and increased hippocampal and cortical neurogenesis. This compound affected the subacute phase by modulating microglial response and by increasing local production of insulin-like growth factor-I, known to be a key player in neuronal survival and neurogenesis. The relative wide therapeutic window, coupled with its efficacy in attenuating further degeneration and enhancing restoration, makes poly-YE a promising immune-based candidate for stroke therapy. *(Stroke. 2007;38(part 2):774-782.)*

Key Words: neuroprotection ■ neurogenesis ■ reactive microglia ■ stroke

Previously, we have demonstrated that central nervous system (CNS) trauma spontaneously evokes a beneficial, T-cell–mediated immune response, which reduces neuronal loss.1 In the damaged CNS tissue, CNS-specific T cells accumulate and become reactivated on recognizing and interacting with their corresponding autoantigens presented to them by local antigen-presenting cells.2,3 This in turn leads to the production of specific neurotrophic factors (eg, brain-derived neurotrophic factor) by T cells, and to the proper activation of microglia/macrophages.4,5 Enhancing the activity of CNS-specific T cells (by a well-regulated passive or active immunization) was found to be beneficial in various animal models of CNS injuries.6–8 The ability to maintain autoimmunity in healthy individuals, without developing autoimmune disease, was shown to be regulated by naturally occurring CD4+CD25+ regulatory T cells. However, recovery from CNS injury can benefit from a transient elimination or decreased activity of these cells.9 Compounds that can down-regulate the constitutive suppression of regulatory T cells (Treg) were therefore considered by us as potential candidates.

We found that poly-YE, a high-molecular-weight (22 to 45 kDa) copolymer that was shown to exert modulatory effects on the immune system,10,11 is capable of downregulating the activity of the regulatory T cells, and used this copolymer to facilitate the spontaneous response of effector T cells recognizing antigens associated with a CNS insult. Our findings showed that a single administration of poly-YE in rats subjected to an ischemic stroke (permanent middle cerebral artery occlusion [MCAO]) produced long-lasting clinical and behavioral benefits, along with neuroprotection and increased neurogenesis, starting from the subacute phase.

Materials and Methods

Animals
Sprague-Dawley male rats, aged 8 to 12 weeks, and C57Bl/6 male mice, aged 7 to 8 weeks, were supplied by Harlan Biotech (Jerus-
lem, Israel) and were handled according to the ARVO resolution on the use of animals in research. The study was approved by the IAUC of Proneuron Biotechnologies, Ltd, and the National Ethics Committee of the Israeli Council on Animal Experimentation.

Permanent MCAO in Rats
MCAO was preformed using a nylon filament as previously described.15

Measurement of Lesion Size
The effect of poly-YE on early infarct volume was measured 48 hours after MCAO and treatment with 0.5 mg poly-YE/rat or vehicle. From each brain, six 2-mm-thick coronal slices were cut with the aid of a brain slicer matrix (Braintree Scientific) and stained with 2% triphenyltetrazolium chloride, as described elsewhere.13 For testing the effect of poly-YE on cell loss at late stages (6 weeks after MCAO), brains were sectioned while frozen at 50 μm and stained with cresyl violet. The cross-sectional area of both the intact and stroke-damaged hemisphere was measured using unbiased stereology procedure. The area of the infarcted hemisphere was subtracted from the area of the intact hemisphere and expressed as a percentage of the intact hemisphere. This was done in 13 evenly spaced sections through the brain and an average percent of tissue loss was analyzed.

Treatment With poly-YE
On completion of surgery the rats were randomly assigned to different treatment groups. All rats were injected once subcutaneously (SC) at the indicated times either with the designated dosages of poly-YE (Sigma-Aldrich) in a final volume of 1 mL PBS or with PBS only (control). Rats were weighed before MCAO and twice weekly thereafter over the indicated time period.

Neurological Assessment
Neurological severity scores (NSS) were computed as the sum of a number of ratings assigned to each of 11 parameters of posture and locomotion.14 The rats were evaluated twice a week, from 24 hours after MCAO until the end of the experimental period, by an investigator who was blinded to their treatment.

Testing of Behavior in a Morris Water Maze
Starting 21 to 23 days after occlusion, rats were given 3 trials per day, on 4 consecutive days, to find a hidden platform located 1.5 cm below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15 On day 5 the platform was placed above the water level, below the water surface in a pool 1.4 m in diameter, as previously described.15

Statistical Analysis
Statistical calculations were performed using standard functions of Microsoft Excel, supplemented with the StatistiXL add-in package, which provides functions for advanced General Linear Model and nonparametric analyses. Because of large differences in variance between groups, and to obviate the need for data transformation, the data presented in Figure 3 were analyzed using nonparametric statistics. The data presented in Figure 4 were transformed to a normal distribution by application of an empirically optimized function (√Y - 1800), and the data for the ipsilateral and contralateral dentate gyrus of each rat were separately assessed by repeated-measures ANOVA.

Immunoistochemistry
For BrdU staining, tissue sections (25-μm width) were washed with PBS and incubated for 30 minutes in 2N HCl at 37°C. Sections were blocked for 1 hour with blocking solution (PBS containing 20% normal horse serum and 0.5% Triton X-100). Tissue sections were then stained overnight with the primary antibodies (Abs): rat anti-BrdU (1:100; Oxford Biotechnology, Kidlington, Oxfordshire, UK), rabbit anti–microtubule-associated protein (MAP)-2 (1:1000; Chemicon, Temecula, CA), goat anti-doublecortin (anti-doublecortin [DCX]; 1:200; Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-β-III tubulin (1:1000; Chemicon), and mouse anti-neuron–specific nuclear protein (anti-NeuN; 1:150; Chemicon). For labeling of microglia we used FITC-conjugated Bandeiraea simplicifolia isolecitin B4 (IB-4; 1:50; Sigma-Aldrich) and mouse anti-class II major histocompatibility complex protein (anti-MHC-II; 1:40) Abs (IQ Products, Groningen, The Netherlands). For labeling of astrocytes/progenitor cells we used mouse anti-Nestin (1:1000; Chemicon) and rabbit anti-glial fibrillary acidic protein (anti-GFAP) Abs (1:200; DAKO, Glostrup, Denmark). For detection of insulin-like growth factor (IGF)-I expression we used goat anti-IGF-I Ab (1:20; R&D Systems, Minneapolis, MN). Secondary antibodies were Cy-2–conjugated donkey anti-mouse, Cy-3-conjugated donkey anti-rabbit, and Cy-3-conjugated donkey anti-rabbit (1:200; Jackson ImmunoResearch, West Grove, PA).

Quantification
Loss of hippocampal neurons was measured in brains that were removed from euthanized rats, promptly immersed in 10% buffered formalin for 24 hours (to avoid autolysis), and then transferred to 70% alcohol. Coronal hippocampal slices (100-μm-thick) were cut with the rat brain matrix and were stained with hematoxylin and eosin. All stained necrotic cells in the CA1, CA2, and CA3 hippocampal regions of the ischemic and contralateral sides of each slice were counted under a light microscope, and the number of necrotic cells per slice was calculated for each hemisphere. Data were averaged over 2 to 4 hippocampal slices for each rat. For immunohistochemical analysis of cell proliferation and hippocampal neurogenesis, 6 coronal sections per rat brain, spanning the entire dentate gyrus were taken. Proliferation and differentiation were assessed using confocal microscopy (Zeiss LSM 510) by counting cells that were double-labeled with BrdU and NeuN in the dentate gyrus. An estimate of the total number of labeled cells per dentate gyrus was obtained as previously described.15 Cortical neurogenesis was evaluated by counting cells that were double-labeled with BrdU and MAP-2, DCX, or Nestin in the ipsilateral cortex. At least 2 coronal sections per rat were included in the analysis of cortical neurogenesis. To quantify cortical neurogenesis, the total combined volume of the selected sections was multiplied by the number of cells counted per unit surface area of each histological section. IGF-I immunoreactivity was assayed by measurement of the fluorescence intensity per unit area using ImageProPlus software. The same software was used to measure the areas occupied by MHC-II–stained and IB-4–stained cells.

Results
Poly-YE Improves the Neurological Outcome After Stroke
Using an in vitro bioassay for assessment of Treg activity,16,17 we tested the possible effect of poly-YE on effector T cells (Teff) and Treg cells. We found that poly-YE downregulates the suppressive effect of naturally occurring regulatory T cells, and changes the cytokine-secretion profile of the activated Treg cells (see supplemental Figure I, available online at http://stroke.ahajournals.org). We tested the therapeutic effect of SC-injected poly-YE in a rat model of permanent MCAO by examining neurological functions
In 3 separate experiments poly-YE (0.5 mg per rat) or PBS (control) was injected immediately after MCAO (Figure 1A), or with a delay of 6 hours (Figure 1B) or of 24 hours (Figure 1C). All rats (including controls) showed some recovery with time, reflected by a substantial reduction in NSS. Neurological recovery in all 3 experiments was significantly better in the poly-YE–treated rats than in the controls (repeated-measures ANOVA; $P=0.0013$, $P=0.0136$, and $P=0.0451$ for injections given immediately, 6 hours after MCAO, and 24 hours after MCAO, respectively). Repeated-measures ANOVA disclosed a highly significant treatment effect ($P=7\times10^{-6}$), while indicating that the time of injection was not a significant factor ($P=0.87$ for poly-YE, $P=0.44$ for PBS, $P=0.81$ for pooled data). Thus, poly-YE injection significantly improved neurological recovery even when delayed for as long as 24 hours after MCAO.

Next we injected rats, 24 hours after MCAO, with different doses of poly-YE or PBS and assessed the NSS over a period of 6 weeks to determine whether the effect of the treatment is long-lasting (Figure 1D). A significant dose-response treatment effect was evident ($P=0.044$, repeated-measures ANOVA), with poly-YE at doses of 0.5 mg/rat and 1 mg/rat resulting in significantly lower NSS scores at the end of the experiment (Student-Neuhls-Krahl tests performed for $P=0.05$). After 6 weeks the residual impairment in the treated rats was lower than in the PBS control group.
rats was only half of that in the controls, implying that poly-YE treatment had long-lasting effects. Body weights of the rats were monitored for 6 weeks after MCAO as an indicator of their general health. Rats treated with poly-YE showed, on average, a smaller initial weight loss and a larger overall weight gain (Figure 1E; \( P=0.041 \), ANOVA). Poly-YE effect on body weight gain was associated with neurological improvement in the 2 higher dosages (1 mg/rat and 0.5 mg/rat) whereas the lower dosage (0.15 mg/rat) seemed to be ineffective.

**Poly-YE Attenuates Behavioral Deficits After Stroke**

In addition to neurological activity, we assessed the long-term effect of a single injection of poly-YE on behavioral and cognitive functions using the Morris water maze. Rats were injected with poly-YE or PBS immediately after MCAO, and 3 to 3.5 weeks later they were trained for 4 days to locate and mount a hidden platform in the water maze. During the training period the MCA-occluded rats showed significant deficits in spatial learning abilities relative to naïve rats, often failing to acquire the ability to complete the task. No significant effect of poly-YE treatment was detectable at this stage (results not shown). Sham-operated rats completed the task normally, indicating that the poor performance of the MCA-occluded rats was related to the damage induced by MCAO rather than general postoperative trauma. On day 5 the platform was raised so that it was visible above the water surface, and each MCA-occluded rat was allowed one attempt to locate and mount it. Rats injected with PBS (control) performed poorly, with 7 of the 12 rats swimming randomly around the platform and failing to complete the task within the allotted time (Figure 2A). Data were analyzed in terms of reciprocal time, corresponding to “rate” of task completion. Rats treated with poly-YE performed significantly better (\( P=0.041 \); two-tailed \( t \) test; Figure 2B). There were no differences in swimming velocity between the groups (\( P=0.19 \); two-tailed \( t \) test; 25.4±2.2 cm/s\(^{-1}\) in the control group and 19.6±2.9 cm/s\(^{-1}\) in the poly-YE-treated group), indicating that the difference was behavioral rather than physical. This impression was reinforced by the strong negative correlation between swimming velocity and reciprocal time (Pearson correlation; \( r=-0.85 \)), with the fastest swimming observed in the rats that took the longest to complete the task.

**Poly-YE Attenuates Hippocampal Cell Loss**

We speculated that treatment with poly-YE would mainly target degenerative processes that occur after the hyperacute phase, and thus we were not expecting to detect a short-term effect on infarct volume. Infarct volumes were measured 48 hours after MCAO and immediate treatment (PBS, \( n=11 \); 1 mg poly-YE, \( n=14 \)), using the triphenyltetrazolium chloride histological–staining technique. Differences in infarct volume between controls and treated rats were not significant at that time point (mean ischemic volumes±SD were 178±110 mm\(^3\) and 200±104 mm\(^3\), respectively; \( P=0.614 \), two-tailed \( t \) test). Nevertheless, the extent of tissue loss measured 6 weeks after MCAO tended to be greater in the control rats (\( n=10 \)) than in poly-YE treated rats (\( n=11 \); mean values of lost volume±SD were 40±21% and 25±14%, respectively; \( P=0.064 \), two-tailed \( t \) test).

Brain damage after ischemia results from pathophysiological events in the infract area and the penumbra, and in remote brain regions, such as the hippocampus. Rats were subjected to MCAO followed immediately by injection of PBS or 1 mg of poly-YE. Histological examination of the hippocampus in the damaged (ipsilateral) side of the brain 48 hours later showed large numbers of necrotic cells in the PBS-treated controls, whereas in the poly-YE–treated rats their numbers were significantly reduced (Figure 3A and 3B). The reduction in cell necrosis induced by poly-YE treatment was so dramatic that the ipsilateral and contralateral sides were indistinguishable (\( P=0.25 \), Wilcoxon 2-tailed test).

**Poly-YE Promotes Neurogenesis After Stroke**

Recent studies have shown that immune cells play a key role in maintaining adult neurogenesis, and that T-cell–activated microglia can induce neuronal differentiation from adult neural progenitor cells. We therefore examined whether treatment with poly-YE, in addition to its neuroprotective action, could also induce neurogenesis.

In rats subjected to MCAO and then immediately treated with PBS or 1 mg of poly-YE, neurogenesis in the hippocam-
pus was assessed by injecting the cell proliferation marker BrdU. Because BrdU is known to exert cytotoxic effects on proliferating lymphocytes,\(^\text{21}\) it was administered only on days 7 through 9 after MCAO. Rats were killed 28 days after MCAO, and neurogenesis was evaluated by staining of coronal hippocampal sections with antibodies against BrdU and NeuN (a marker of postmitotic neurons). We counted the newly formed BrdU \(\rightarrow\) NeuN \(\rightarrow\) cells in the granular cell layer of the hippocampal dentate gyrus of poly-YE–treated and control rats (Figure 4). An overall increase in the number of newly formed neurons was found in the dentate gyri of poly-YE–treated rats relative to PBS-treated controls (Figure 5A; \(P=0.047\), repeated-measures ANOVA). Notably, the increase was observed in both ipsilateral and contralateral sides, suggesting that a systemic response (eg, via CNS-specific T cells), facilitated by poly-YE, supports neurogenesis in a site not directly affected by MCAO. Studies have demonstrated that ischemic or traumatic brain injury can induce neurogenesis in regions of the brain that are normally non-neurogenic.\(^\text{22}\) We stained coronal sections containing the cortical lesion site for BrdU and the progenitor-cell marker Nestin. Numerous Nestin-stained cells could be seen surrounding the lesion site 28 days after MCAO (Figure 5A), most of them colabeled with BrdU (Figure 5B) and the astrocytic marker glial fibrillary acidic protein (GFAP; not shown). Within the lesion site, no viable neurons (expressing the neuronal marker MAP-2) were detectable (Figure 5A). Because opinions are divided as to whether cortical neurogenesis is feasible,\(^\text{22}\) we included several neuronal markers in our analysis and used 3-D confocal scanning microscopy to examine their colocalization with BrdU. Within the ischemic penumbra, we detected newly formed cells colabeled with BrdU and the early neuronal differentiation markers β-III tubulin and doublecortin (Figure 5C and 5D). We could also detect newly formed neurons with mature phenotypes, indicated by BrdU/NeuN (Figure 5E) and BrdU/MAP-2 double staining (Figure 5F through 5I). Some of the BrdU+/MAP-2+ neurons were seen within the area adjacent to the lesion (Figure 5F) and had short processes (Figure 5G), implying that conditions in that area were not optimal for cell growth and connectivity. In contrast, newly formed mature neurons with highly developed pyramidal morphology were detected in cortical areas more remote from the lesion (Figure 5H and 5I). The dense and uniform BrdU-labeling, found on neurons

Figure 3. Effect of poly-YE on hippocampal cell death after stroke. A, Total numbers of necrotic cells per section in the CA1, CA2, and CA3 hippocampal regions (*\(P=0.016\), Mann-Whitney 2-tailed test; \(n=5\) and \(n=4\) for PBS-treated and poly-YE-treated rats, respectively). Data are means±SEM. B, Densely stained necrotic cells are arrayed around the hippocampus on the ischemic side in a coronal section from the hippocampus of a control rat (left) and a poly-YE-treated rat (right), 48 hours after MCAO (bar=500 \(\mu\)m).
in both early and late maturation stages, suggests that it did not result from apoptosis or DNA repair.

To avoid possible artifacts caused by nonspecific fluorescence staining of myelin debris which might interfere with discrete staining of neuronal nuclear markers, we chose to quantify BrdU\(^{+}\) cells colabeled with MAP-2 or DCX, which have a clear dendritic morphology. We took special care to count only those cells that exhibit the typical neuronal morphology and in which BrdU-staining appeared in the center of the cell. Quantitative analysis revealed an increase of almost 3-fold in the numbers of newly formed neurons with a mature phenotype (BrdU\(^{+}\)/MAP-2\(^{+}\)) in the cortices of poly-YE–treated rats relative to PBS-treated rats (Figure 5J). However, the numbers of newly differentiating neurons (BrdU\(^{+}\)/DCX\(^{+}\)) and progenitor cells/proliferating astrocytes (BrdU\(^{+}\)/Nestin\(^{+}\)) were not significantly different between the poly-YE–treated rats and the controls (Figure 5J).

In addition to its effect on neurogenesis, we found that poly-YE induced long-lasting changes in microglial phenotype in the thalamus (ie, increased expression of MHC-II), which were associated with increased IGF-I expression by Nestin\(^{+}\)/GFAP\(^{+}\) cells (see supplemental Figure I).

**Discussion**

The results presented above show that administration of poly-YE as late as 24 hours after the induction of ischemic stroke greatly improves subsequent recovery. The therapeutic effect of poly-YE was demonstrated in rats by neurological criteria (NSS scores), behavioral parameters (Morris water maze task), and weight gain. The beneficial effects of poly-YE...
include both prevention of ischemia-induced remote, delayed degeneration (neuroprotection), and enhancement of repair (neurogenesis). The therapeutic time window (of 24 hours) seemed to be significantly wider than that of most of the current and candidate therapies for stroke.

Postinjury immune response has often been perceived as part of the detrimental cascade that causes neuronal death and impairs neurogenesis. Consequently, a number of anti-inflammatory agents have been tested in animal models of stroke, with the goal of limiting the recruitment and activation of inflammatory cells. This approach was indeed found to reduce infarct size and neurological deficits if applied within a few hours of ischemic onset. However, a controlled clinical trial with the anti-inflammatory corticosteroid methylprednisolone resulted in an unexpected increase in short-term mortality.

We have proposed that resident microglia and circulating CNS-specific T cells contribute to CNS plasticity. Importantly, the activity of such immune cells can be detrimental if not well regulated. In line with this concept, a study
in humans demonstrated an association between the incidence of myelin-specific T cells and improved recovery from traumatic brain injury.30

Recent studies have shown that ischemic brain injury can trigger neural cell renewal also in areas outside of the classic neurogenic compartments (the hippocampal dentate gyrus and the subventricular zone),22 including in the poststroke human brain.31 Indeed, the neurogenesis-promoting effect of poly-YE treatment was evident in both the hippocampus and in the cerebral cortex. The overall increase in cortical neurogenesis after poly-YE treatment might account for part of the observed behavioral and neurological improvement. The fact that increased number of new neurons with mature phenotype was detected in the hippocampus and cortex of the poly-YE–treated rats further supports the notion that increased neurogenesis can be induced by poly-YE treatment. The remarkable wide therapeutic window, poly-YE can probably explain this effect. Given its immunomodulatory mode of action and its broad spectrum of targets, poly-YE can be of interest in the treatment of complex acute neurodegenerative disorders such as stroke.

The observed increase in IGF-I production by Nestin+ cells and the higher incidence of MHC-II+ microglia/macrophages seen in the thalamus of the poly-YE–treated rats further suggest that immunomodulation, which allows a well-controlled T-cell–mediated response, contribute for creating neurogenic conditions after an ischemic brain insult. This notion is in line with previous findings by our group.4,20

At this stage, we cannot rule out the possibility that immune-cell populations other than Treg cells are also affected by poly-YE in vivo, because other studies have shown that this compound can induce activation of γδ T-cells in vitro.10 Regardless of the specific T-cell subtypes directly affected by poly-YE, further studies are needed to define where the dialogue between poly-YE–induced immune response and the injured CNS takes place (ie, peripheral lymph nodes, cerebrospinal fluid, injured parenchyma).

In conclusion, the findings of this study introduce poly-YE as a novel immune-based therapy for the treatment of complex acute neurodegenerative disorders such as stroke. Our findings emphasize the feasibility of therapeutic intervention at the subacute phase if a proper choice of the therapy is made. Given its immunomodulatory mode of action and its remarkably wide therapeutic window, poly-YE can probably be used concomitantly or sequentially with other therapies for stroke.

Acknowledgments

The authors thank Dr Elisheva Yonish-Rouach for her contribution in discussing the results and writing the manuscript. M.S. is the incumbent of the Maurice and Ilse Katz Professorial Chair in Neuroimmunology.

Sources of Funding

The work was supported by Proneuron Biotechnologies Ltd., Weizmann Science Park, Ness-Ziona, Israel.

Disclosures

Y.G., I.S., S.S., I.V., M.K., A.L., J.B.M., and E.Y. are or were employees of Proneuron Biotechnologies Ltd. There are no other conflicts of interest reported.

References


A Novel Immune-Based Therapy for Stroke Induces Neuroprotection and Supports Neurogenesis
Yaniv Ziv, Arseny Finkelstein, Yona Geffen, Jonathan Kipnis, Igor Smirnov, Suzi Shpilman, Irena Vertkin, Michal Kimron, Aya Lange, Torsten Hecht, Klaus G. Reyman, Jonathan B. Marder, Michal Schwartz and Eti Yoles

Stroke. 2007;38:774-782
doi: 10.1161/01.STR.0000255784.27298.23
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/38/2/774

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/